A recently approved immunization drug is helping to limit the severity of a respiratory disease that afflicts young children ...

The following is a summary of “Parent Perspectives on Nirsevimab for Their Newborn,” published in the November 2024 issue of ...

RSV is the most common cause of hospitalization in infants under 1 year old. The infection can spread to the lungs and cause ...

IDWeek 2024 was held at the Los Angeles Convention Center in Downtown Los Angeles, CA, USA, from 16–19 October. Phoebe Hall ...

Seasonal maternal respiratory syncytial virus (RSV) vaccination and nirsevimab for infants demonstrate cost-effectiveness, according to two studies published online Nov. 25 in Pediatrics.

University of Michigan and Centers for Disease Control and Prevention (CDC) investigators determined that both maternal ...

Infants will be able to receive a free immunisation to protect them against serious illness from respiratory syncytial virus (RSV), under a new $16.6 million NSW ...

Seasonal maternal respiratory syncytial virus (RSV) vaccination and nirsevimab for infants demonstrate cost-effectiven ...

When should pregnant women get the RSV vaccine? Research suggests that 32 weeks into pregnancy ensures the best antibody ...

Pregnant individuals are advised to receive the RSV vaccine between 32 and 36 weeks of pregnancy, with a recommended window from September to January, although RSV can persist until mid-May. Older ...

The Centers for Disease Control and Prevention recommends that everyone 6 months and older receive at least one dose of the ...

The following is a summary of “RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing,” published in the ...